Long-term follow-up of axillary node-positive breast cancer patients receiving adjuvant tamoxifen alone: Patterns of recurrence

被引:30
作者
Fisher, BJ
Perera, FE
Cooke, AL
Opeitum, A
Stitt, L
机构
[1] London Reg Canc Ctr, Dept Biometry & Outcome Measures, London, ON N6A 4L6, Canada
[2] Univ Western Ontario, London Reg Canc Ctr, Dept Radiat Oncol, London, ON, Canada
[3] Winnipeg Canc Ctr, Dept Radiat Oncol, Winnipeg, MB, Canada
[4] Windsor Reg Canc Ctr, Dept Radiat Oncol, Windsor, ON, Canada
[5] London Reg Canc Ctr, Dept Biometry & Outcome Measures, London, ON N6A 4L6, Canada
来源
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS | 1998年 / 42卷 / 01期
关键词
breast cancer; tamoxifen; postmenopausal; local-regional recurrence;
D O I
10.1016/S0360-3016(98)00177-1
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To determine the patterns, incidence and risk factors for local-regional recurrence in patients with Stage II and III breast cancer treated with adjuvant tamoxifen alone, without adjuvant radiation, Material and Methods: The records of patients referred to the London Regional Cancer Centre with a diagnosis of breast cancer between 1980-1989 were reviewed. During this time period, it was the policy of the institution to omit local-regional radiation to patients receiving adjuvant systemic therapy, One hundred and fifty axillary node-positive Stage Il and III breast cancer patients received adjuvant tamoxifen alone without postoperative local-regional radiation; these patients form the basis of this report. Results: Median follow-up was 67 months for the entire patient group and 85 months for the living patients. During this time, 42% of patients developed a recurrence, 22% first recurred in local-regional sites. The total incidence of local-regional recurrence (including those patients who first relapsed with systemic metastases) was 30%, Of the segmental mastectomy patients, 13% had recurrences in the intact breast. Of the modified radical mastectomy patients, 10% developed chest wall recurrences. Five percent of recurrences were first in the axilla and 6% in the supraclavicular nodes. Five-year actuarial survival for the entire patient group was 79% and disease-free survival was 60%, with a median disease-free survival time of 87 months. Five-year local-regional relapse-free survival was 76%. Five-year local-regional relapse-free survival was < 76% for those patients with 4 or more positive axillary nodes, regardless of tumor size. On univariable analysis, positive resection margins, number of positive axillary nodes, menopausal status, and negative estrogen and progesterone receptors were significant for isolated local-regional recurrence. On multivariable analysis, only positive resection margins and negative receptors remained significant. In terms of regional recurrence specifically, negative estrogen and progesterone-receptor status and positive resection margins were, again, prognostically significant. Conclusions: Postmenopausal women receiving adjuvant tamoxifen who have positive resection margins, greater than or equal to 4 positive axillary nodes and/or negative estrogen and progesterone receptors, are at higher risk of local and regional recurrence and should, therefore, receive local-regional radiation. (C) 1998 Elsevier Science Inc.
引用
收藏
页码:117 / 123
页数:7
相关论文
共 23 条
[1]  
AMES FC, 1990, SURG CLIN N AM, V70, P1115
[2]   BREAST-CANCER IN ELDERLY WOMEN - A CANCER-RESEARCH CAMPAIGN TRIAL COMPARING TREATMENT WITH TAMOXIFEN AND OPTIMAL SURGERY WITH TAMOXIFEN ALONE [J].
BATES, T ;
RILEY, DL ;
HOUGHTON, J ;
FALLOWFIELD, L ;
BAUM, M .
BRITISH JOURNAL OF SURGERY, 1991, 78 (05) :591-594
[3]  
BAUM M, 1985, LANCET, V1, P836
[4]  
CIATTO S, 1991, TUMORI, V77, P328
[5]   TAMOXIFEN WITH AND WITHOUT RADIATION AFTER PARTIAL MASTECTOMY IN PATIENTS WITH INVOLVED NODES [J].
COOKE, AL ;
PERERA, F ;
FISHER, B ;
OPEITUM, A ;
YU, N .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1995, 31 (04) :777-781
[6]  
FISHER B, 1992, SEMIN SURG ONCOL, V8, P153
[7]   A RANDOMIZED CLINICAL-TRIAL EVALUATING TAMOXIFEN IN THE TREATMENT OF PATIENTS WITH NODE-NEGATIVE BREAST-CANCER WHO HAVE ESTROGEN-RECEPTOR POSITIVE TUMORS [J].
FISHER, B ;
COSTANTINO, J ;
REDMOND, C ;
POISSON, R ;
BOWMAN, D ;
COUTURE, J ;
DIMITROV, NV ;
WOLMARK, N ;
WICKERHAM, DL ;
FISHER, ER ;
MARGOLESE, R ;
ROBIDOUX, A ;
SHIBATA, H ;
TERZ, J ;
PATERSON, AHG ;
FELDMAN, MI ;
FARRAR, W ;
EVANS, J ;
LICKLEY, HL ;
KETNER, M .
NEW ENGLAND JOURNAL OF MEDICINE, 1989, 320 (08) :479-484
[8]   10-YEAR RESULTS FROM THE NATIONAL SURGICAL ADJUVANT BREAST AND BOWEL PROJECT (NSABP) CLINICAL-TRIAL EVALUATING THE USE OF L-PHENYLALANINE MUSTARD (L-PAM) IN THE MANAGEMENT OF PRIMARY BREAST-CANCER [J].
FISHER, B ;
FISHER, ER ;
REDMOND, C .
JOURNAL OF CLINICAL ONCOLOGY, 1986, 4 (06) :929-941
[9]   The impact of tamoxifen on breast recurrence, cosmesis, complications, and survival in estrogen receptor-positive early-stage breast cancer [J].
Fowble, B ;
Fein, DA ;
Hanlon, AL ;
Eisenberg, BL ;
Hoffman, JP ;
Sigurdson, ER ;
Daly, MB ;
Goldstein, LJ .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1996, 35 (04) :669-677
[10]  
GAZET JC, 1988, LANCET, V1, P679